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Abstract
Introduction and objective. There are some clinical situations where a high level of HDL cholesterol (HDL-C) may be 
unfavourable. In these situations, HDL-C may undergo some changes, and even if its quantity is within the reference range, 
its quality is no longer the same.  
Brief description of state of knowledge. Diabetes is the state of elevated oxidative stress. Studies conducted to-date 
have revealed an increased production of the reactive forms of oxygen as the result of tissue damage in diabetes patients. 
The expression ‘dysfunctional HDL’ has been coined in the literature to describe high-density lipoproteins that lose their 
antioxidative and anti-inflammatory properties, that is, HDL-C that loses its basic functions. Recent observational studies 
have confirmed that the atheroprotective activity of properly functioning HDL-C is frequently impaired in clinical situations 
associated with oxidative stress. The presented review lays the foundation for a new approach to understanding how the 
functional properties of HDL help reduce cardiovascular risk.  
Conclusions. In the light of presented findings it seems that there is a need to seek a better diagnostic marker than HDL-C 
level. This study presents some possible directions for future research to bring us closer to the full understanding of the 
HDL particle and its role in patients with ischemic heart disease and type 2 diabetes.
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INTRODUCTION
The incidence of diabetes continues to rise worldwide, 
with the number of patients exceeding 425 million adults 
and expected to rise to 642 million people by 2040 [1]. 
This growing incidence has been related to urbanization 
and dramatic lifestyle changes, particularly in developed 
countries. As a result, there has been an increase in the 
incidence of risk factors for numerous diseases, including 
type 2 diabetes [2]. So far, several modifiable risk factors have 
been associated with type 2 diabetes, including overweight, 
unhealthy diet, and lack of physical activity [2]. The most 
recent evidence shows that the growing incidence of diabetes 
constitutes a huge health burden for global society [2].
The major cause of mortality and morbidity in diabetic 
patients is cardiovascular disease (CVD) [3]. Moreover, in 
patients with diabetes and concomitant CVD, the risk of 
major adverse cardiac events is increased, compared with 
patients without diabetes [3]. On average, it is estimated that 
patients with type 2 diabetes die prematurely, about 5–10 
years earlier than those without type 2 diabetes, mostly due 
to coronary heart disease (CHD) [4]. In Europe, the treatment 
of CVD accounts for a significant proportion of health care 
costs attributed to type 2 diabetes (10%–12%) [1].
Dyslipidaemia is the major risk factor for atherosclerosis, 
although to-date the mechanism of this association has not 
been fully elucidated. Low-density lipoprotein cholesterol 
(LDL-C) has been determined as the major atherogenic 
lipoprotein, and its central role in atherosclerosis has been 
confirmed in numerous studies [5–7]. On the contrary, 
epidemiological, pathological, and experimental studies 
have demonstrated that high-density lipoprotein cholesterol 
(HDL-C) may protect against coronary artery disease [8, 
9]. Moreover, HDL-C has been shown to reduce the risk of 
atherosclerosis by multiple pathophysiological mechanisms.
Despite the atheroprotective properties of HDL-C, some 
most recent clinical studies have identified individuals 
with a significant atherosclerotic burden despite normal 
or elevated levels of HDL cholesterol [8]. Nascent discoidal 
HDL-C is composed of cholesterol, apolipoprotein A-I 
(apoA-I) and phospholipids. Its particles undergo lipidation 
and remodeling by a series of reactions mediated by 
ATP-binding cassette sub-family G member 1 (ABCG1), 
membrane-associated ATP-binding cassette transporter 
A1 (ABCA1), hepatic lipase, endothelial lipase, cholesteryl 
ester transfer protein (CETP), and phospholipid transfer 
protein [10, 11]. This complex structure and involvement 
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in various metabolic pathways are the potential causes of 
qualitative and quantitative modifications of HDL particles, 
which may result in the loss of at least a few pleiotropic 
properties of HDL-C and the development of new potentially 
proatherogenic activities. Therefore, the HDL-C level itself is 
not always a good indicator of its atheroprotective features.
Since it has been established that a significant number 
of CHD events in patients with type 2 diabetes occur in 
individuals with normal or even elevated HDL-C level, it 
is necessary to identify biomarkers with a better predictive 
value in this group of patients. In addition, these patients 
have atherogenic dyslipidemia and therefore may develop 
atherosclerosis.
The mechanisms that deprive HDL-C of its cardioprotective 
properties are poorly understood. Therefore, the presented 
review aimed to discuss some of the possible directions for 
future research to bring us closer to a full understanding of 
the HDL particle and its role in patients with ischemic heart 
disease and type 2 diabetes.
Biocharacteristics of HDL-C. The HDL particle consists of 
lipids and proteins (apolipoproteins) with different 
biochemical activities. So far, over 100 proteins bound to 
HDLs have been identified, with apoA-I as the main surface 
protein. Immunoseparation is used to separate HDL particles 
containing apoA-I from those containing both apoA-I and 
apolipoprotein A-II (apoA-II) (Fig. 1 and 2).
Figure 1. HDL particle containing apoA-I
Figure 2. HDL particle containing ApoA-I-A-II
It has been suggested that these apolipoproteins have 
different metabolic properties and thus may have a different 
atheroprotective potential [12]. This cited experimental study 
revealed reduced anti-inflammatory activity in transgenic 
mice with the over-expression of apoA-II in HDL particles. 
The authors also hypothesized that patients with ischemic 
heart disease and type 2 diabetes may show differences in 
HDL protein profiles.
Interestingly, little is known about proteins other than 
apoA-I contained in normal and in dysfunctional HDL-C, and 
data on the potential role of different HDL-C subpopulations 
in the inflammatory process are still limited [13]. Meanwhile, 
a growing body of evidence indicates that the determination 
of HDL subpopulations might significantly improve our 
knowledge on cardiovascular risk [14]. It is believed that 
such data would be particularly valuable for diabetic patients.
HDL-C as a protective factor. HDL-C is currently being 
widely studied in experimental and clinical research. It has 
been recognized as an independent protective factor in CHD. 
This was first shown in the Framingham Heart Study, which 
confirmed an inverse correlation between HDL-C and the 
incidence of CHD [15]. HDL-C exerts anti-inflammatory 
and antioxidant effects and protects against atherosclerosis, 
as shown by a considerable amount of experimental data 
[16]. There are many recognized pathways that have been 
proposed to account for the involvement of HDL-C in 
protective mechanisms against CHD.
HDL-C and its major protein, apoA-I, are essential for 
mediating reverse cholesterol transport, which is a multi-step 
process involving cholesterol transfer from peripheral tissues, 
such as arterial walls, back to the liver via plasma for 
excretion. The HDL transformation cycle is shown in 
Figure 3.
Figure 3. HDL-C transformation cycle
This function likely plays an important role in the 
atheroprotective mechanism of HDL-C. Other protective 
activities of HDL-C include the removal or detoxication 
of oxidized sterols and phospholipids. It also exerts 
antithrombotic actions and has a beneficial effect on 
endothelial cells [17, 18] (Tab. 1).
Effects of a pharmacological increase in HDL levels. 
A meta-analysis of randomized controlled trials has not 
confirmed the hypothesis that any agent raising HDL level 
should decrease the number of cardiovascular events [19].
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LDL cholesterol (LDL-C)-lowering agents. The finding 
that elevated LDL-C and low HDL-C level is associated with 
increased cardiovascular mortality encouraged the search 
for targeted drug treatments. The main assumption for new 
therapies was either to increase HDL-C level or lower LDL-C 
level, or to achieve both. Since then, lowering of LDL-C level 
by using statins has repeatedly been found to reduce the risk 
of cardiac events and all-cause mortality in the setting of 
secondary and primary prevention [19].
Multiple strategies targeting the inhibition of proprotein 
convertase subtilisin/kexin type 9 (PCSK9) have emerged as 
effective modalities for LDL-C lowering. PCSK-9 monoclonal 
antibodies are the most advanced to-date in clinical 
development, and in 2015 alirocumab and evolocumab were 
approved for clinical use by regulatory agencies. Adverse 
events associated with these medications are minimal. 
Importantly, most studies confirmed that PCSK9 improve 
clinical CVD outcomes, although the results of a long-term 
study are yet to be reported [20].
Contrary to the above findings, the authors of the most 
recent study published in the European Heart Journal have 
found no associations between PCSK9 and apoA-I, HDL-C, 
lipoprotein(a) and high-sensitivity C-reactive protein. 
Furthermore, the baseline levels of PCSK9 did not predict 
the first cardiovascular events [21]. In addition, it should 
be noted that the more general use of PCSK-9 monoclonal 
antibodies has thus far been limited by the high cost [20].
Nowadays, with the generic availability of statins and 
their widespread use, the aim of reducing LDL level has 
been fulfilled. However, the achievement of the second goal, 
namely, elevating HDL level, seems to be more complicated.
HDL-C-elevating agents. The three main substances 
proposed to increase HDL level with the aim of reducing 
cardiovascular morbidity and mortality are niacin, fibrates, 
and the recently developed CETP inhibitors. Different classes 
of lipid-modifying agents are presented in Table 2.
A recent study, HPS2-Thrive, has reported that the addition 
of niacin to statin-based LDL-C-lowering therapy did not 
significantly reduce the risk of major vascular events, but 
it did increase the risk of serious adverse events (such as 
gastrointestinal complications, bleeding, musculoskeletal 
side effects, or increased incidence of diabetes) [22, 23].
Fibrates have been shown to consistently reduce some 
cardiovascular outcomes but only in patients with high 
serum triglyceride levels and low HDL-C level. Fibrates, 
unlike CETP, increase HDL-C level mostly through the 
stimulation of apoA-I production [24].
In the class of CETP inhibitors, three agents have been 
studied: anacetrapib, dalcetrapib, and torcetrapib. Two 
studies involving the promising torcetrapib were stopped 
prematurely because of adverse events in the treatment arms, 
and one study involving dalcetrapib was also discontinued 
because of futility [25–27]. Although the above CETP 
Table 1. Main features of HDL cholesterol
Features of HDL cholesterol Description
Anti-inflammatory and 
antioxidant (detoxification 
of oxidized sterols and 
phospholipids)
Protective role against atherosclerosis. Main antioxidant protein of HDL is Apo A-I. Its role strongly depends on myeloperoxidase, which 
promotes endothelial dysfunction and plaque rupture. Excessive production of malondialdehyde and phospholipid aldehyde resulted 
from the fact that oxidative stress deprives the ability of Apo A-I to promote atheroprotective features. On the other hand, paraoxanase-1 
in HDLs limits lipid oxidation and provides additional atheroprotective effects.
Reverse cholesterol 
transport
Protective role against atherosclerosis by transporting the cholesterol from arterial walls and peripheral tissues to the liver and activating 
nitric oxide synthase.
Antithrombotic activity
The effect of HDL-C on platelet function remains unclear. Some studies showed that HDL particles changed platelet signaling pathways by 
limiting intraplatelet cholesterol overload and inhibiting nitric oxide and prostacyclin production. Decreased HDL-C level was associated 
with high platelet reactivity both in patients with ST-elevation myocardial infarction and stable coronary artery disease.
Healing the endothelium
HDL particles inhibit the VCAM-1 expression. The inhibition of this process was observed in diabetes and cardiovascular diseases and led 
to increased inflammatory activity by macrophage adhesion to activated endothelial cells.
Table 2. Lipid-modifying agents
Pharmacological targets Description
Statins
Reduced cardiac events and all-cause mortality, mostly by lowering LDL cholesterol. The effect on HDL-C is more complicated 
and less well-investigated.
Niacin
Adding niacin to statin did not significantly reduce the risk of cardiovascular disease and increased the risk of major side-
effects (e.g. gastrointestinal, bleeding, musculoskeletal)
Fibrates Fibrates increase HDL-C level mostly through the stimulation of apolipoprotein A-I production.
CETP inhibitors (anacetrapib, 
dalcetrapib, and torcetrapib, TA-8995)
Beneficial effects of TA-8995 on lipid profiles in patients with dyslipidaemia, well-tolerated by patients. No evidence of the 
effectiveness of other agents, or trials discontinued due to adverse events.
PCSK-9 monoclonal antibodies
Evolocumab
Alirocumab
The FOURNIER study proved that it significantly reduces major vascular events in patients with stable atherosclerotic 
cardiovascular disease, also patients with prior MI. Patients closer to their most recent MI, with multiple prior MIs or residual 
multivessel CAD benefit from substantial risk reductions with evolocumab.
Evolocumab significantly reduces cardiovascular risk in patients with and without diabetes.
ODYSSEY OUTCOMES study showed that alirocumab reduces the risk of MI and ischemic stroke. Also, it significantly reduces 
LDL-C and other atherogenic lipid parameters and is generally well tolerated in persons with diabetes and atherosclerotic 
cardiovascular disease.
Both agents are safe and well-tolerated, but high cost and lack of cost-effectiveness limit their routine use.
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inhibitors have not been able to prevent clinically important 
events, a number of clinical trials (such as ACCELERATE 
and REVEAL) with other CETP inhibitors are still ongoing, 
and the results are anticipated in the next few years.
The authors of a recent study published in The Lancet, 
TULIP, presented the results for a novel CETP inhibitor 
called TA-8995. This agent has been shown to have beneficial 
effects on lipid profile in patients with dyslipidemia and to 
be well-tolerated by patients. Moreover, it did not cause any 
serious adverse events [28]. In this randomized, double-blind, 
placebo-controlled study, HDL-C levels were increased in 
patients receiving TA-8995, with larger increases correlating 
with higher doses. Although the authors underlined that 
further studies were needed to determine the effect of TA-
8995 on cardiovascular outcomes, the results are promising.
Although the results of the TULIP study are encouraging, 
most of the attempts to reduce cardiovascular events or 
mortality by increasing HDL-C level using those three 
different classes of drugs on top of statins have been 
unsuccessful so far [29].
Insight from genetic studies. A large-scale meta-analysis 
of genome-wide association studies revealed that plasma 
lipid levels are affected by common genetic variants, which 
explains from 10%–12% of the total variance and from 
25%–30% of genetic variability in plasma lipid phenotypes 
[30]. This means that although a portion of the genetic 
contribution to variation in plasma lipids and lipoproteins 
has been characterized, there is still variance that remains 
without known assignment [31].
The evidence from a cumulative meta-analysis and 
replication studies suggests that a more careful examination 
of the common variants is required, considering the available 
genetic data. This might help explain the portions of missing 
heritability, as well as clarify the pathways and mechanisms 
involved in lipid metabolism and CVD. The authors of a 
recent article published in the American Journal of Human 
Genetics suspect the possibility of identification of potential 
loci in which rare single nucleotide polymorphisms (SNPs) 
with large effects on the phenotype can be discovered [32]. 
To investigate the causal role of HDL-C and triglycerides in 
CVD using multiple instrumental variables for Mendelian 
randomization, Holmes et  al. developed weighted allele 
scores based on SNPs with established associations with 
HDL-C, LDL-C, and triglycerides. The findings from this 
analysis (which included over 62,000 participants with 12,000 
CVD events) support the causal effect of triglycerides on the 
risk of CVD, while the involvement of HDL-C has not been 
confirmed [33].
Should we aim at increasing HDL-C and apoA-I levels? It 
is still unclear whether an increase in HDL-C and apoA-I 
level is associated with a reduced risk of cardiovascular 
events. A recent study by Boekholdt et al. showed that an 
increase in HDL-C level was not associated with a lower risk 
of major cardiovascular events, independently of established 
risk factors. However, the authors reported an association 
between increased apoA-I level and a reduced risk of major 
cardiovascular events [34]. These results were consistent 
with the data reported by the EPIC-Norfolk and Rotterdam 
Studies, which suggested that the association between 
changes in HDL-C level caused by lipid-modifying therapy 
and risk of CHD was mostly explained by established risk 
factors [35]. Based on combined data from those studies, 
the change in HDL-C level caused by lipid-modifying 
therapy was associated with a reduced cardiovascular risk 
when adjusted for age, gender, and baseline HDL-C level. 
However, this association was attenuated and was not 
significant when further adjusted for non-HDL-C (calculated 
as total cholesterol level minus HDL-C level, as LDL-C and 
triglyceride level were not measured for all participants 
during all examination rounds), as well as for smoking 
history, prevalent diabetes, systolic blood pressure, body 
mass index, use of antihypertensive medications, previous 
myocardial infarction, prevalent angina, and previous stroke. 
These studies provided no evidence to support a significant 
benefit of increasing HDL-C level, independently of the effect 
of lowering non-HDL-C.
A systematic review and meta-regression analysis of 
randomized controlled trials testing lipid-modifying 
interventions showed that an increase in HDL-C level was 
not associated with cardiovascular outcomes [36]. The analysis 
included 108 randomized trials involving 299310 participants 
at risk of cardiovascular events. There was no association 
between treatment-induced rise in HDL-C level and risk ratios 
for CHD-related or total mortality and CHD events. A study 
performed by Grover et al. showed that the change in HDL-C 
level was a strong independent risk factor for CV events [37]. 
In contrast, a recent published meta-analysis showed that 
a rise in HDL-C level was not associated with a lower risk 
of major cardiovascular events independent of established 
risk factors [34]. However, an increase in apoA-I level was 
associated with cardiovascular risk such that patients with 
the largest increases had the lowest cardiovascular risk [34]. 
The authors argued that although these results did not provide 
evidence for the potential causality of the association between 
increased apoA-I level and reduced cardiovascular risk, they 
supported further research into apoA-I-modifying therapies.
In summary, most recent studies have questioned the 
hypothesis that lipid-modifying therapy should be aimed 
at increasing HDL-C level. On the other hand, there have 
been studies showing that an increase in apoA-I level is 
associated with a reduced cardiovascular risk, independently 
of established risk factors, which reinforces the rationale for 
using apoA-I as a target for the treatment of atherosclerosis.
Selected indices of HDL and their superiority over chemical 
measurement of HDL-C level. Recent studies of drugs 
that increase HDL-C level, but without reducing the rate 
of cardiovascular events or progression of atherosclerosis, 
revealed the limitations of the specific agents tested [38–
40]. HDL particles (HDL-P) are quite heterogeneous and 
because their activity cannot be inferred from the chemically 
measured plasma HDL-C level, some recent studies have 
focused on measuring other indices of HDL, such as the 
function, size, or concentration (number) of HDL-P. It 
is hypothesized that these indices may be better clinical 
markers of atheroprotective effects of HDL [41].
A review published in 2011 by Asztalos et al. confirmed 
that HDL subclasses differ in physical and chemical 
properties, protein and lipid composition, metabolism, 
and physiological functions, and, consequently, they have 
different pathophysiological significance [41]. The results 
from the large, randomized, double-blind JUPITER trial 
showed that among patients who did not receive lipid-
lowering therapy, HDL-C, apoA-I, and HDL-P level showed 
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similar inverse associations with CVD [42]. However, among 
individuals who were treated with rosuvastatin, HDL-P had a 
stronger and statistically significant inverse association with 
CVD in comparison with HDL-C or apoA-I level. The authors 
suggested that HDL-P may be a better marker of residual risk 
than HDL-C or apoA-I among individuals receiving potent 
statin therapy to achieve very low LDL-C level. It has also 
been shown that the association of HDL-C level with CVD 
is influenced by insulin resistance, abdominal obesity, and 
inflammation [43]. In contrast, HDL-P appeared to be much 
less influenced by these factors [44].
So far, only HDL-C has been the standard parameter 
of HDL measured in clinical practice. However, it may be 
important to assess also other parameters in clinical trials 
of HDL-elevating therapies. Considering the results of the 
recent studies, it seems that HDL-P may be an alternative 
to HDL-C as a marker of HDL-related cardiovascular risk.
HDL-C efflux capacity. HDL-C exerts numerous 
antiatherosclerotic effects that are not readily reflected by 
HDL-C level [45]. The key function of HDL is to promote 
reverse cholesterol transport from peripheral tissues to 
the liver, and the critical initial step in this transport is 
cholesterol efflux from macrophages to HDL [46]. Cholesterol 
efflux by HDL is also required for lipoprotein signaling 
in endothelial cells, which underlies the ability of HDL 
to activate endothelial nitric oxide synthase, promote 
endothelial repair, and induce angiogenesis [47]. Impaired 
cholesterol efflux capacity has also been shown to correlate 
with increased platelet reactivity in vitro [48].
Macrophage-specific cholesterol efflux capacity has 
been directly and causally linked to the prevention of 
atherosclerosis in animal models [46]; therefore, it has 
become the focus of recent research as a promising indicator 
of HDL function with possible antiatherosclerotic effects 
[49]. Khera et al hypothesized that cholesterol efflux 
capacity is a determinant of atherosclerotic burden that 
was independent of HDL-C level [50]. The authors examined 
the relationship of efflux capacity with HDL-C level and 
two measures of atherosclerosis, namely, carotid intima-
media thickness and angiographically confirmed CHD. They 
showed that cholesterol efflux was inversely correlated with 
both measures, independently of HDL-C level. In addition, 
cholesterol efflux was associated with a higher level of apoA-I, 
also independently of HDL-C level. Moreover, a recent 
population-based cohort study involving individuals without 
CVD at baseline showed that cholesterol efflux capacity 
was inversely correlated with incident atherosclerotic CVD 
[51]. This association was also observed after adjustment 
for traditional cardiovascular risk factors, HDL-C level, 
and number of HDL-P. Rohatgi et  al. suggested that the 
association of HDL function with cardiovascular risk is 
explained by processes other than those shown by the HDL-C 
level, HDL-P concentration, or traditional cardiovascular 
risk factors [51]. Finally, Hutchins et al. recently reviewed 
evidence that cholesterol efflux capacity is a strong inverse 
predictor of incident and prevalent CVD. The authors 
suggested that impaired macrophage cholesterol efflux to 
HDL contributes to the risk of CVD [52].
It should be noted that cholesterol efflux from macrophages 
represents only a small fraction of the overall flux through the 
reverse-cholesterol-transport pathway. However, this might 
be the most relevant component in atheroprotection [53].
HDL and type 2 diabetes. In glucose-resistant tissue observed 
in such conditions as metabolic syndrome, nonenzymatic 
glycosylation of HDL particles was shown to occur, which was 
considered as one of the main mechanisms of dysfunctional 
HDL. This modification significantly impairs the reverse 
cholesterol transport from peripheral tissues via ABCA1 
and ABCG1 transporters. Glycated substrate molecules are 
also susceptible to oxidation and lose antioxidant properties 
themselves. In addition, they show a dramatically lower 
potential to inhibit the release of proinflammatory cytokines 
(tumour necrosis factor alpha and interleukin 1b) from 
activated macrophages. Also, the glycosylation process 
reduces the HDL-mediated activation of lecithin-cholesterol 
acyltransferase, an enzyme that catalyzes the conversion 
of cholesterol to cholesteryl ester. It has been shown that 
without this conversion, mature spherical HDL particles 
are not formed and excess peripheral tissue cholesterol is 
less efficiently transported to the liver for excretion from 
the body [54].
The usual HDL-induced inhibition of endothelial expression 
of vascular cell adhesion molecule 1 is impaired in patients 
with type 2 diabetes and CVD [55]. This anti-inflammatory 
activity of HDL is lost due to favoring the adhesion of 
macrophages to activated endothelial cells in patients with 
diabetes [56]. Moreover, it has been shown that the HDL 
paricle in this group of patients loses its vasorelaxant effects. 
It has also been confirmed that in this group of patients, HDL 
has a reduced ability to stimulate endothelial nitric oxide 
production and endothelial-dependent vasodilation [57].
Interestingly, Riwanto et al showed that HDL in patients 
with type 2 diabetes with CHD does not inhibit endothelial 
apoptosis because it fails to activate antiapoptotic proteins, 
while simultaneously stimulating proapoptotic pathways 
[58]. Furthermore, a study of diabetic patients showed that 
cholesterol efflux was positively associated with the total 
number of HDL-P but not with HDL-C or apoA-I level [59].
HDL and oxidative stress. In some clinical situations, high 
HDL-C level might be unfavourable. For example, in acute 
phase response, as seen after surgery, or in inflammation 
or diabetes, HDL may undergo some changes that affect 
its quality even though its level remains within the normal 
range [60–62].
Recent studies have focused on so-called dysfunctional 
HDL, which is HDL deprived of its primary function as 
well as atheroprotective and anti-inflammatory actions 
[63]. The latest observational studies have shown that the 
antiatherosclerotic effect of normally functioning HDL 
is frequently impaired in clinical states associated with 
systemic inflammation [63]. It is hypothesized that common 
atherosclerotic risk factors, such as dyslipidaemia, diabetes, 
hypertension, sedentary life style, obesity, cigarette smoking, 
or unhealthy diet, are all characterized by the presence of 
systemic inflammation and oxidative stress and may explain 
why HDL loses its protective features [64]. It has been also 
suggested that both systemic inflammation and oxidative 
stress involve the conversion of HDL to a dysfunctional form, 
which is no longer cardioprotective [50, 65, 66].
The conversion of antiatherogenic HDL molecules to 
proatherogenic dysfunctional HDL is caused by the loss 
of activity of antioxidant enzymes, such as paraoxonase-1 
(PON-1), and also by chemical modifications of apoproteins 
and enhancement of acute phase protein response [67]. 
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It has been shown that in such conditions, acute phase 
proteins are the major protein component of HDL particles, 
constituting 27% of the whole composition. However, the 
mechanism underlying this transformation is still unclear, 
and there are no widely accepted methods for determining 
HDL function in selected groups of patients. It has been 
suggested that these transformed HDL particles with reduced 
antioxidative activity may become a more useful biomarker of 
cardiovascular risk than the ‘old’ HDL. The effects of HDL’s 
conversion to its dysfunctional form are presented in Table 3.
It is believed that antiatherogenic effects of the higher 
numbers of HDL-P may be related to protein or other cargo 
(e.g. apoA-I, PON-1, myeloperoxidase [MPO]), rather than to 
cholesterol cargo of HDL [45]. The main antioxidant protein 
in HDL is apoA-I, whose role strictly depends on MPO. 
Recent studies have revealed that deficiency in apoA-I plays 
a major role in the development of atherosclerotic lesions, 
and that there is a close relationship between high MPO 
level and the development of atherosclerotic plaque. High 
apoA-I level was shown to be associated with a reduced risk of 
atherosclerotic plaque and inhibition of atherosclerosis [68]. 
MPO is found in neutrophils and monocytes and plays an 
important role in killing microorganisms. MPO catalytically 
consumes nitric oxide in vitro and in vivo and promotes lipid 
peroxidation and activation of protease cascades involved 
in plaque fissuring or rupture. This enzyme also induces 
the expression of endothelial cell tissue factor, oxidative 
conversion of LDL, and modification of apoA-I, impairing its 
ability to promote cholesterol efflux [69]. Finally, circulating 
MPO level strongly correlates with the degree of endothelial 
dysfunction [70].
Recent studies have revealed the unfavourable effect 
of MPO in numerous clinical conditions associated with 
systemic inflammation and oxidative stress, such as type 2 
diabetes [71]. It has been shown that the expression of MPO 
is markedly enhanced in human atherosclerotic lesions. It 
binds with apoA-I and modifies HDL-C. When apoA-I is 
oxidized by MPO, its ability to promote cellular cholesterol 
efflux by ABCA1 pathway is diminished [66]. In addition, 
biochemical studies have revealed that oxidation of specific 
tyrosine and methionine residues in apoA-I contributes to 
the loss of ABCA1 activity. Therefore, one potential pathway 
involves oxidative damage of HDL proteins by MPO. A 
mass spectrometric analysis demonstrated that the levels 
of 3-chlorotyrosine and 3-nitrotyrosine, two characteristic 
products of MPO, are elevated in HDL isolated from patients 
with established CVD. In summary, it may be hypothesize 
that plasma levels of MPO and its activity are higher in type 
2 diabetes patients with CVD than in non-diabetic patients.
There are also other enzymes that can potentially modify 
HDL proteins. A number of studies have shown that the 
antioxidant activity of HDL is associated with the levels of 
PON-1 protein. PON-1 is an enzyme that is synthesized in the 
liver and is present in HDL particles consisting of apoA-I. PON-
1 slows down lipid oxidation and contributes to antioxidant 
and atheroprotective effects of HDL. Its protective properties 
result not only from the ability to eliminate potential oxidants 
but also from the ability to neutralize their final products to 
nontoxic particles. Recent studies have shown a low level of 
PON-1 in patients with type 2 diabetes [72]. Rani et al. reported 
a significant reduction in PON1 activity along with a decrease 
in HDL-C level in diabetic patients in comparison with non-
diabetic individuals. Moreover, the authors stated that the 
progression of diabetes over the years resulted in a much 
higher reduction in PON-1 activity, as confirmed by Pearsons’ 
correlation analysis. Thus, they concluded that diabetes, as a 
condition associated with oxidative stress, leads to a reduction 
in the antioxidant activity of PON-1. Also, lower serum level 
of PON-1 has been associated with higher morbidity and 
mortality related to cardiovascular complications in patients 
with type 2 diabetes. Taken together, the above findings 
suggest that PON-1 may be a better predictor of atherosclerotic 
risk in type 2 diabetes than HDL.
Some recent studies have demonstrated that plasma MPO 
level has a significant inverse correlation with PON-1 level 
in patients with stable and unstable angina pectoris, and 
suggested that the imbalance between pro-oxidants and 
antioxidants may contribute to the progression of coronary 
plaque instability [73]. Based on current knowledge, the 
authors of the current study believe that there may be such a 
correlation in patients with stable ischemic disease and type 
2 diabetes, but this issue requires further studies.
HDL and malondialdehyde. Diabetes mellitus is a condition 
associated with oxidative stress. Extensive research has 
shown that an increased production of reactive oxygen 
species results in tissue injury in such pathological conditions 
as diabetes or chronic degenerative diseases [74]. Some recent 
studies have demonstrated that malondialdehyde (MDA) 
and phospholipid aldehydes can be produced under the 
condition of oxidative stress and contribute to tissue injury 
and dysfunction by depleting glutathione, leading to the 
modification of proteins, lipids, and DNA [74]. Recently, 
Shao et  al. have shown that the exposure to increased 
concentrations of MDA progressively and dramatically 
deprived ApoA-I of its ability to promote cholesterol efflux 
[75, 76]. Moreover, it has been reported that MDA levels are 
elevated in diseases associated with an increased risk of CVD, 
such as diabetes [77]. Importantly, immunochemical analyses 
demonstrated that HDL isolated from atherosclerotic tissue 
contained higher levels of MDA-modified proteins than 
HDL originating from the plasma of apparently healthy 
humans [76]. This suggests that MDA modifies HDL in 
human atherosclerotic tissue.
HDL and coagulation. Several studies have confirmed the 
anticoagulant properties of HDL-C, although there have 
also been studies suggesting that it has pro-coagulant 
effects [78–80]. This is due to the fact that HDL-C is a very 
heterogeneous group of particles. ApoA-I, the predominant 
protein of HDL-C, was shown to have antiatherogenic 
properties mostly associated with reverse cholesterol 
transport [81–83]. However apoA-I oxidation could modify 
its atheroprotective features [78, 84, 85]. On the other hand, 
apoA-II, the second major HDL particle, has been found to 
be associated with pro-coagulant effects and progression of 
atherosclerosis [86–88]. Of note, the EPIC-Norfolk study 
demonstrated that apoA-II was not associated with coronary 
Table 3. Effects of HDL-C conversion to its dysfunctional form
Loss of antioxidant activity
Chemical modifications of apoproteins
Enhancement of acute phase proteins
522
Annals of Agricultural and Environmental Medicine 2018, Vol 25, No 3
Katarzyna Nessler, Adam Windak, Rafał Grzybczak, Michał Bohdan Nessler, Aleksander Siniarski, Grzegorz Gajos. High-density lipoprotein (HDL) cholesterol…
artery disease and its major complication––myocardial 
infarction. Coagulant properties of HDL-C, and particularly 
their effects on platelet function, still remain unknown. A few 
studies showed that HDL particles change platelet signaling 
pathways by limiting intraplatelet cholesterol overload and 
inhibiting the production of nitric oxide and prostacyclin 
[89, 90]. It is still not known whether HDL particles influence 
the tissue expression on the endothelial surface [78, 91, 92]. 
Nevertheless, decreased HDL-C level was associated with 
high platelet reactivity, both in patients with ST-segment 
elevation myocardial infarction and in those with stable 
coronary artery disease [93, 94].
Association of HDL with diet and physical activity. The 
effect of lifestyle interventions, such as the use of diet, on HDL 
function in patients with type 2 diabetes remains unclear 
[95]. However, for example, the traditional Mediterranean 
diet is now widely recommended in the prevention of CVD.
A recent meta-analysis reported that a lifestyle intervention 
resulted in a significant improvement of risk factors 
associated with CVD, such as body mass index, haemoglobin 
A1c, systolic blood pressure, and diastolic blood pressure, 
in patients with type 2 diabetes. However, HDL-C was 
not significantly changed by the intervention [96–98]. The 
described lifestyle intervention included an exercise and diet 
component and at least one other component such as smoking 
cessation, behavior modification, or counseling. A further 
analysis of the data revealed an improvement in HDL and 
haemoglobin A1c levels only for interventions that included 
pharmacotherapy [93].
In contrast, a recent multicentre randomized clinical trial, 
Look AHEAD (Action for Health in Diabetes), showed a 
significant effect of an intensive lifestyle intervention on 
HDL-C in comparison with the control group [99]. This 
association was not shown for other risk factors. The 
intervention included diet modification and physical activity. 
In order to increase dietary compliance, a portion-controlled 
diet was used, with liquid meal replacements provided free 
of charge and recommendations to use other portion-
controlled items. In addition, the authors aimed to encourage 
the participants to achieve at least 175 minutes of physical 
activity per week, using activities similar in intensity to brisk 
walking. Behavioural strategies included self-monitoring. 
During each of the four years of this study, HDL-C level 
in the group of patients receiving the lifestyle intervention 
was approximately 8%–9% higher, compared with baseline 
levels. The results of another recent study confirmed that 
encouraging adults with newly diagnosed type 2 diabetes to 
interrupt prolonged periods of sedentary time with physical 
activity may be an effective strategy to maintain metabolic 
health [100]. The study showed that reallocation of 30 minutes 
of long-bout sedentary time with light physical activity was 
associated with higher HDL-C level.
To the knowledge of the authors of the presented study, 
there are only a few studies that analyzed the correlation 
between diet and apoA-I and apoA-II profiles in patients 
suffering from CHD and type 2 diabetes. Also, only a few 
studies have investigated gender-related differences in 
HDL-C level or apoA-I and apoA-II level in response to 
diet. Nevertheless, some evidence suggests that women could 
respond differently to diet compared with men, partly due to 
sex hormones [101, 102]. In fact, the response of HDL-C to 
alterations in dietary fats and carbohydrates appears to be 
greater in women than in men [101]. Another recent study 
has revealed a more pronounced decrease in apoA-II level 
in men than in women after introducing an experimental 
Mediterranean diet [103]. Moreover, the LDL-C to HDL-C 
ratio was also significantly decreased in men; therefore, the 
authors suggested that the decrease in apoA-II level in men 
in response to the Mediterranean diet did not affect the 
metabolism of plasma lipids and lipoproteins.
The above-results show that further studies are needed 
to improve our knowledge on the effect of diet and physical 
activity on HDL-C, apoA-I, and apoA-II level in patients with 
type 2 diabetes. This might allow the development of more 
specific nutritional strategies for the prevention of CVD.
CONCLUSIONS
Type 2 diabetes is currently considered a worldwide epidemic; 
therefore, it is crucial to find an effective therapeutic strategy 
for this disease. The progress in our knowledge about lipid 
disorders and their influence on the prognosis of patients with 
CHD and type 2 diabetes may soon require the development 
of a new and more specific lipid panel, as the one used in 
current medical practice may prove insufficient. The standard 
measurement of HDL-C level may not be enough to reflect 
its antiatherogenic potential because cardiovascular events 
have been widely observed in type 2 diabetes patients with 
normal or even increased HDL-C level. Therefore, the search 
for new markers with a better prognostic value is needed in 
this patient group.
The association between dysfunctional HDL and type 2 
diabetes is important, both for physicians and for clinical 
researchers, but to-date the issue has not been fully elucidated. 
Currently, several studies investigating these relationships are 
being conducted. The entire March 2015 issue of the European 
Heart Journal focused on lipoproteins and diabetes [104]. The 
journal’s Editor-in-Chief, Thomas Luscher, underlined that 
despite all the progress that had been made, there were still 
some unanswered questions concerning the involvement 
of lipids in CVD. In particular, he mentioned such issues 
as the management of homozygous autosomal dominant 
hypercholesterolaemia, the role of HDL-C, and the problem 
of obesity [105–107]. He also underlined that all attempts to 
modify HDL-C pharmacologically have failed so far [104].
All the data reviewed above lay the foundation for a new 
approach to understanding how the functional properties 
of HDL help reduce the risk of CVD. Therefore, in the light 
of those findings, there is a need to find a better diagnostic 
marker than HDL-C level. It is hoped that the elucidation 
of the mechanisms of oxidative stress and its effects on HDL 
in type 2 diabetes may take us a step further in the ongoing 
search for new lipid markers.
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